ARWR

Q: What is the price of Arrowhead Pharmaceuticals (ARWR) today?

The price of Arrowhead Pharmaceuticals (ARWR) today is $ 63.82, with return of 233.96% compared to the last year. The price of Arrowhead Pharmaceuticals (ARWR) started the year trading around $ 66.39 and today it is at $ 63.82. Follow the real-time price chart, the historical price of Arrowhead Pharmaceuticals (ARWR) and international markets.

Q: When does Arrowhead Pharmaceuticals (ARWR) pay dividends?

Arrowhead Pharmaceuticals (ARWR) did not distribute dividends in the last year.

Q: Is Arrowhead Pharmaceuticals (ARWR) worth it?

Currently, Arrowhead Pharmaceuticals (ARWR) is priced at $ 63.82, with a P/E of 43.70%, representing a deviation of 17% from its historical average P/E. In the last year, the stock showed a variation of 233.96 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 233.96%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Arrowhead Pharmaceuticals (ARWR) stock?

Investing in stocks of Arrowhead Pharmaceuticals (ARWR) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Arrowhead Pharmaceuticals (ARWR) yield today?

The yield of Arrowhead Pharmaceuticals (ARWR) was -3.17% in the last month, 233.96% in the last year and -26.98% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Arrowhead Pharmaceuticals (ARWR) today, the total investment would be $ 6,382.00, based on the current price of $ 63.82.If past performance were to repeat, the return on your investment would be:In 1 year: $ 21,313.33In 5 years: $ 4,660.14In 10 years: $ 103,375.64It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Arrowhead Pharmaceuticals Inc.

Price

$ 63.82

return (12m)

233.96%

p/e

43.70

p/bv

15.71

DIVIDEND YIELD

0.00%

price ARWR

ARWR

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of ARWR

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-3.17%

3 months

54.68%

1 year

233.96%

2 years

115.39%

5 years

-26.98%

10 years

1,519.80%

Fundamentals ARWR

review the fundamentals of Arrowhead Pharmaceuticals shares

P/E

43.70

Sector: -3.65 Industry: -3.65

P/SALES RATIO (PSR)

8.10

Sector: -3.80 Industry: -3.80

P/BV

15.71

Sector: 1.99 Industry: 1.99

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

12.61%

Sector: -64.67% Industry: -64.67%

ROE

35.94%

Sector: -67.85% Industry: -67.85%

ROIC

29.78%

Sector: -1,117.20% Industry: -1,117.20%

NET MARGIN

18.54%

Sector: -41.21% Industry: -41.21%

GROSS MARGIN

100.00%

Sector: 38.73% Industry: 38.73%

OPERATING MARGIN

27.55%

Sector: -41.19% Industry: -41.19%

P/EBITDA

23.87

Sector: -3.64 Industry: -3.64

P/EBIT

25.61

Sector: -3.78 Industry: -3.78

P/ASSET

5.51

Sector: 1.43 Industry: 1.43

BVPS

4.11

Sector: 1.76 Industry: 1.76

EPS

1.48

Sector: -2.06 Industry: -2.06

EQUITY RATIO

0.35

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

49.84%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Arrowhead Pharmaceuticals ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 63.82

Fair Value

$ 0.00

Upside Return potential.

-81.67%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ARWR

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.45	7.25	33.81%	2.15%	$ 574.83 B	28.46%
PFE	20.18	1.68	8.35%	6.24%	$ 156.82 B	12.42%
ABBV	165.20	-151.79	-91.88%	2.94%	$ 394.50 B	4.00%
NVO	13.50	6.95	51.50%	3.54%	$ 211.57 B	33.05%
MRK	16.58	0.00	0.00%	2.69%	$ 302.63 B	28.08%
AZN	63.71	13.03	20.45%	0.81%	$ 598.78 B	16.17%
GILD	23.37	8.83	37.80%	2.07%	$ 189.56 B	27.88%
BMY	17.89	-3.71	-20.72%	4.02%	$ 126.21 B	14.64%
ZTS	21.29	10.46	49.11%	1.57%	$ 56.45 B	28.21%
REGN	17.96	2.59	14.41%	0.45%	$ 80.91 B	31.41%
HALO	15.96	18.86	118.17%	0.00%	$ 9.50 B	47.91%
AMGN	26.86	23.93	89.06%	2.48%	$ 207.15 B	20.98%
MCK	26.89	-1,178.66	-4,383.84%	0.32%	$ 116.69 B	1.09%
VRTX	33.29	7.06	21.22%	0.00%	$ 122.35 B	31.35%
CAH	32.14	-19.78	-61.56%	0.90%	$ 53.41 B	0.68%
ADMA	18.75	9.11	48.57%	0.00%	$ 3.93 B	42.87%
BIIB	18.39	1.62	8.83%	0.00%	$ 29.57 B	15.98%
HRMY	11.64	2.59	22.24%	0.00%	$ 2.16 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

ARWR Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT THE COMPANY Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc.

Average user rating I10

4.0 (5 people)

United States

37 years

Founded: 1989

1997

Time since IPO - 29 years

232

Employees

The Company Arrowhead Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market value of $ 8.84 Billions, having an equity of $ 562.70 Millions.

With a total of 232 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 1.09 Billion, which generated a profit in the amount of $ 202.26 Millions.

As for its main indicators, the Company has a P/E ratio of 43.70, a P/BV ratio of 15.71 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker ARWR.

Market cap

$ 8.84 Billions

Net worth

$ 562.70 Millions

US$ 562,700,000.00

Assets

$ 1.60 Billion

US$ 1,604,180,000.00

Total Shares Outstanding

137.00 Millions

137,000,000

Average Daily Trading Volume

$ 3.24 Millions

US$ 3,242,980.92

Sector

Health Care

Industry

Biotechnology

ARWR

ARWR revenue and profits

Financial Results ARWR

DRAG THE FRAME TO SEE MORE DATA

ARWR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 934.75 58,25% (12M)

P/E

26.89

0.32%

ROE

-4,383.84%

P/BV

-1,178.66

CAH - Cardinal Health

$ 220.79 77,13% (12M)

P/E

32.14

0.90%

ROE

-61.56%

P/BV

-19.78

JNJ - Johnson & Johnson

$ 243.45 61,60% (12M)

P/E

21.45

2.15%

ROE

33.81%

P/BV

7.25

PFE - Pfizer

$ 27.58 17,79% (12M)

P/E

20.18

6.24%

ROE

8.35%

P/BV

1.68

MRK - Merck & Co.

$ 121.41 52,82% (12M)

P/E

16.58

2.69%

ROE

0.00%

P/BV

0.00

ABBV - AbbVie

$ 231.50 24,01% (12M)

P/E

165.20

2.94%

ROE

-91.88%

P/BV

-151.79

AZN - AstraZeneca

$ 205.55 185,32% (12M)

P/E

63.71

0.81%

ROE

20.45%

P/BV

13.03

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 934.75 58,25% (12 M)

P/L

26.89

0.32%

ROE

-4,383.84%

P/VP

-1,178.66

CAH - Cardinal Health

$ 220.79 77,13% (12 M)

P/L

32.14

0.90%

ROE

-61.56%

P/VP

-19.78

JNJ - Johnson & Johnson

$ 243.45 61,60% (12 M)

P/L

21.45

2.15%

ROE

33.81%

P/VP

7.25

PFE - Pfizer

$ 27.58 17,79% (12 M)

P/L

20.18

6.24%

ROE

8.35%

P/VP

1.68

MRK - Merck & Co.

$ 121.41 52,82% (12 M)

P/L

16.58

2.69%

ROE

0.00%

P/VP

0.00

ABBV - AbbVie

$ 231.50 24,01% (12 M)

P/L

165.20

2.94%

ROE

-91.88%

P/VP

-151.79

AZN - AstraZeneca

$ 205.55 185,32% (12 M)

P/L

63.71

0.81%

ROE

20.45%

P/VP

13.03

Frequently Asked Questions

What is the price of Arrowhead Pharmaceuticals (ARWR) today?

The price of Arrowhead Pharmaceuticals (ARWR) today is $ 63.82, with return of 233.96% compared to the last year. The price of Arrowhead Pharmaceuticals (ARWR) started the year trading around $ 66.39 and today it is at $ 63.82. Follow the real-time price chart, the historical price of Arrowhead Pharmaceuticals (ARWR) and international markets.

When does Arrowhead Pharmaceuticals (ARWR) pay dividends?

Arrowhead Pharmaceuticals (ARWR) did not distribute dividends in the last year.

Is Arrowhead Pharmaceuticals (ARWR) worth it?

Currently, Arrowhead Pharmaceuticals (ARWR) is priced at $ 63.82, with a P/E of 43.70%, representing a deviation of 17% from its historical average P/E. In the last year, the stock showed a variation of 233.96 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 233.96%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Arrowhead Pharmaceuticals (ARWR) stock?

Investing in stocks of Arrowhead Pharmaceuticals (ARWR) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Arrowhead Pharmaceuticals (ARWR) yield today?

The yield of Arrowhead Pharmaceuticals (ARWR) was -3.17% in the last month, 233.96% in the last year and -26.98% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Arrowhead Pharmaceuticals (ARWR) today, the total investment would be $ 6,382.00, based on the current price of $ 63.82.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 21,313.33
In 5 years: $ 4,660.14
In 10 years: $ 103,375.64

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

ARWR

Arrowhead Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return of ARWR

review the fundamentals of Arrowhead Pharmaceuticals shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY RATIO

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT THE COMPANY Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc.

United States

37 years

1997

232

PROFIT X PRICE ARWR

Financial Results ARWR

ARWR cash flow

asset growth - ARWR

ARWR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

MRK - Merck & Co.

ABBV - AbbVie

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

MRK - Merck & Co.

ABBV - AbbVie

AZN - AstraZeneca

Frequently Asked Questions